Companies › Celyad Oncology
3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Feb 2035.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CYAD-02 CAR-T cell therapy targeting CLEC12A | CLEC12A | Phase 1 | Acute Myeloid Leukemia | Feb 2035 |
| CYAD-101 Allogeneic NKG2D-based chimeric antigen receptor T-cell therapy | NKG2D | Phase 1 | Unresectable Metastatic Colorectal Cancer | Feb 2036 |
| CYAD-211 Allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell | BCMA | Phase 1 | Relapse/Refractory Multiple Myeloma | Feb 2037 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04167696 | CYAD-02 | Phase 1 | Acute Myeloid Leukemia | Oncology | Feb 2035 |
| NCT03692429 | CYAD-101 | Phase 1 | Unresectable Metastatic Colorectal Cancer | Oncology | Feb 2036 |
| NCT04613557 | CYAD-211 | Phase 1 | Relapse/Refractory Multiple Myeloma | Oncology | Feb 2037 |
| NCT04991948 | CYAD-101 | Phase 1 | Unresectable Metastatic Colorectal Cancer | Oncology | May 2038 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.